CA2014130A1 - Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions - Google Patents
Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesionsInfo
- Publication number
- CA2014130A1 CA2014130A1 CA002014130A CA2014130A CA2014130A1 CA 2014130 A1 CA2014130 A1 CA 2014130A1 CA 002014130 A CA002014130 A CA 002014130A CA 2014130 A CA2014130 A CA 2014130A CA 2014130 A1 CA2014130 A1 CA 2014130A1
- Authority
- CA
- Canada
- Prior art keywords
- cytokine
- cytokines
- combination
- treatment
- preneoplastic lesions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 52
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 52
- 230000001855 preneoplastic effect Effects 0.000 title claims abstract description 26
- 230000003902 lesion Effects 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 230000009885 systemic effect Effects 0.000 title abstract description 11
- 108010050904 Interferons Proteins 0.000 claims description 25
- 102000014150 Interferons Human genes 0.000 claims description 25
- 229940079322 interferon Drugs 0.000 claims description 25
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 17
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 230000002925 chemical effect Effects 0.000 claims description 5
- 230000000704 physical effect Effects 0.000 claims description 5
- 238000007910 systemic administration Methods 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000012270 DNA recombination Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108010086123 Macrophage-Activating Factors Proteins 0.000 description 2
- 102000007436 Macrophage-Activating Factors Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000010309 neoplastic transformation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3911720 | 1989-04-11 | ||
| DEP3911720.0 | 1989-04-11 | ||
| DE4005416 | 1990-02-21 | ||
| DEP4005416.0 | 1990-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2014130A1 true CA2014130A1 (en) | 1990-10-11 |
Family
ID=25879777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002014130A Abandoned CA2014130A1 (en) | 1989-04-11 | 1990-04-09 | Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5128126A (enExample) |
| EP (1) | EP0392300B1 (enExample) |
| JP (1) | JPH02304027A (enExample) |
| KR (1) | KR900015754A (enExample) |
| AT (1) | ATE79763T1 (enExample) |
| AU (1) | AU638982B2 (enExample) |
| CA (1) | CA2014130A1 (enExample) |
| DE (1) | DE59000270D1 (enExample) |
| DK (1) | DK0392300T3 (enExample) |
| ES (1) | ES2034790T3 (enExample) |
| GR (1) | GR3005528T3 (enExample) |
| HU (1) | HU206834B (enExample) |
| IE (1) | IE64765B1 (enExample) |
| IL (1) | IL94052A (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| JP2597953B2 (ja) * | 1991-12-10 | 1997-04-09 | 大塚製薬株式会社 | 制癌剤 |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5571797A (en) * | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
| WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| US20020150552A1 (en) * | 2000-09-12 | 2002-10-17 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030082685A1 (en) * | 2001-04-06 | 2003-05-01 | WEICHSELBAUM Ralph R. | Chemotherapeutic induction of egr-1 promoter activity |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2536041A1 (en) * | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
| EP1781284B1 (en) * | 2004-08-25 | 2010-10-13 | The University of Chicago | Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| US20080241100A1 (en) * | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
| EP1977759A1 (en) * | 2007-03-27 | 2008-10-08 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
| JP2010522724A (ja) * | 2007-03-27 | 2010-07-08 | ４エスツェー アクチェンゲゼルシャフト | サイトカインを含有する医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983001198A1 (en) * | 1981-10-08 | 1983-04-14 | Kurt Frimann Berg | Method and composition for treating a patient suffering from interferon-susceptible disorder |
| AU9051882A (en) * | 1981-10-08 | 1983-04-27 | Berg, Kurt Frimann | Method and composition for treating a patient suffering from interferon-susceptible disorders |
| EP0077063B1 (en) * | 1981-10-13 | 1988-03-16 | Exovir, Inc. | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
-
1990
- 1990-03-31 ES ES199090106221T patent/ES2034790T3/es not_active Expired - Lifetime
- 1990-03-31 EP EP90106221A patent/EP0392300B1/de not_active Expired - Lifetime
- 1990-03-31 DK DK90106221.6T patent/DK0392300T3/da active
- 1990-03-31 DE DE9090106221T patent/DE59000270D1/de not_active Expired - Fee Related
- 1990-03-31 AT AT90106221T patent/ATE79763T1/de not_active IP Right Cessation
- 1990-04-09 CA CA002014130A patent/CA2014130A1/en not_active Abandoned
- 1990-04-09 IL IL9405290A patent/IL94052A/en not_active IP Right Cessation
- 1990-04-09 US US07/505,269 patent/US5128126A/en not_active Expired - Fee Related
- 1990-04-10 IE IE129790A patent/IE64765B1/en not_active IP Right Cessation
- 1990-04-10 JP JP2094884A patent/JPH02304027A/ja active Pending
- 1990-04-10 HU HU902145A patent/HU206834B/hu not_active IP Right Cessation
- 1990-04-10 AU AU53105/90A patent/AU638982B2/en not_active Ceased
- 1990-04-11 KR KR1019900004955A patent/KR900015754A/ko not_active Ceased
-
1992
- 1992-08-27 GR GR920401805T patent/GR3005528T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL94052A0 (en) | 1991-01-31 |
| EP0392300A1 (de) | 1990-10-17 |
| HU902145D0 (en) | 1990-07-28 |
| EP0392300B1 (de) | 1992-08-26 |
| HUT54303A (en) | 1991-02-28 |
| ATE79763T1 (de) | 1992-09-15 |
| AU638982B2 (en) | 1993-07-15 |
| AU5310590A (en) | 1990-10-18 |
| IE901297L (en) | 1990-10-11 |
| KR900015754A (ko) | 1990-11-10 |
| US5128126A (en) | 1992-07-07 |
| DK0392300T3 (da) | 1992-09-28 |
| GR3005528T3 (enExample) | 1993-06-07 |
| HU206834B (en) | 1993-01-28 |
| IL94052A (en) | 1995-06-29 |
| ES2034790T3 (es) | 1993-04-01 |
| DE59000270D1 (de) | 1992-10-01 |
| JPH02304027A (ja) | 1990-12-17 |
| IE64765B1 (en) | 1995-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2014130A1 (en) | Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions | |
| US4791101A (en) | Synergistic mixtures of interferons and tumor necrosis factor | |
| RU2128056C1 (ru) | Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами | |
| CA2308116A1 (en) | Low-toxicity human interferon-alpha analog | |
| RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
| KR0165674B1 (ko) | 원발성 흉막암의 치료를 위한 제약 조성물 | |
| IE75896B1 (en) | Double-stranded RNA correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles | |
| EP0527852B1 (en) | Method and compositions for treating injury | |
| JPH04305535A (ja) | 細胞増殖抑制作用または細胞毒作用を有する治療用活性物質の組合せ | |
| EP1450850B1 (en) | Method of administering a thymosin alpha 1 peptide | |
| SHALABY et al. | In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleukin-2 | |
| EP0295559B1 (en) | Pharmaceutical composition for the treatment of tumours | |
| US6255283B1 (en) | Use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (TNF) | |
| Awisati et al. | The role of interferon-α in the management of myelomatosis | |
| Trump et al. | Interferon-α-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma | |
| EP0273778A2 (en) | Synergistic behavior of csf-1 and G-csf | |
| Sasseville et al. | Interferon-induced cutaneous necrosis | |
| KR0169975B1 (ko) | 감마 인터페론 활성을 갖는 폴리펩티드를 함유하는 원발성 흉막암 치료용 제약 조성물 | |
| EP1471974B1 (en) | Tumor necrosis factor combined with interferon in demyelinating diseases | |
| KIMOTO et al. | Interferon treatment of human stomach and breast carcinoma xenografts in nude mice | |
| JPH07101877A (ja) | 血小板減少症治療剤 | |
| Richtsmeier | The interferons | |
| Nolibe et al. | Stimulation of natural killer cytotoxicity by long-term treatment with double-stranded polynucleotides without induction of hyporesponsiveness | |
| JPH04360840A (ja) | 血小板減少症治療剤 | |
| Mohanty et al. | Role of interferon-alpha-2b in the prevention of superficial carcinoma of the bladder recurrence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |